194 related articles for article (PubMed ID: 29673122)
1. Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy.
Muehlberg F; Funk S; Zange L; von Knobelsdorff-Brenkenhoff F; Blaszczyk E; Schulz A; Ghani S; Reichardt A; Reichardt P; Schulz-Menger J
ESC Heart Fail; 2018 Aug; 5(4):620-629. PubMed ID: 29673122
[TBL] [Abstract][Full Text] [Related]
2. Early myocardial oedema can predict subsequent cardiomyopathy in high-dose anthracycline therapy.
Muehlberg F; Kornfeld M; Zange L; Ghani S; Reichardt A; Reichardt P; Schulz-Menger J
ESC Heart Fail; 2023 Feb; 10(1):616-627. PubMed ID: 36404640
[TBL] [Abstract][Full Text] [Related]
3. Anthracycline-Associated T1 Mapping Characteristics Are Elevated Independent of the Presence of Cardiovascular Comorbidities in Cancer Survivors.
Jordan JH; Vasu S; Morgan TM; D'Agostino RB; Meléndez GC; Hamilton CA; Arai AE; Liu S; Liu CY; Lima JA; Bluemke DA; Burke GL; Hundley WG
Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27502058
[TBL] [Abstract][Full Text] [Related]
4. Characterization of critically ill patients with septic shock and sepsis-associated cardiomyopathy using cardiovascular MRI.
Muehlberg F; Blaszczyk E; Will K; Wilczek S; Brederlau J; Schulz-Menger J
ESC Heart Fail; 2022 Aug; 9(4):2147-2156. PubMed ID: 35587684
[TBL] [Abstract][Full Text] [Related]
5. Ultrahigh-field cardiovascular magnetic resonance T1 and T2 mapping for the assessment of anthracycline-induced cardiotoxicity in rat models: validation against histopathologic changes.
Park HS; Hong YJ; Han K; Kim PK; An E; Lee JY; Park CH; Lee HJ; Hur J; Kim YJ; Choi BW
J Cardiovasc Magn Reson; 2021 Jun; 23(1):76. PubMed ID: 34134713
[TBL] [Abstract][Full Text] [Related]
6. Serial Cardiac MRI for Quantification of the Dynamics of Anthracycline-Induced Subclinical Myocardial Injury.
Zheng Y; Liu H; Zhao L; Guan S; Huo H; Li H; Guo J; Peng X; Hao Y; Jin S; Hou Y; Dai X; Liu T; Zhang X
J Magn Reson Imaging; 2023 Nov; 58(5):1533-1541. PubMed ID: 36912379
[TBL] [Abstract][Full Text] [Related]
7. Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy.
Neilan TG; Coelho-Filho OR; Shah RV; Feng JH; Pena-Herrera D; Mandry D; Pierre-Mongeon F; Heydari B; Francis SA; Moslehi J; Kwong RY; Jerosch-Herold M
Am J Cardiol; 2013 Mar; 111(5):717-22. PubMed ID: 23228924
[TBL] [Abstract][Full Text] [Related]
8. Diffuse Myocardial Fibrosis and Inflammation in Rheumatoid Arthritis: Insights From CMR T1 Mapping.
Ntusi NAB; Piechnik SK; Francis JM; Ferreira VM; Matthews PM; Robson MD; Wordsworth PB; Neubauer S; Karamitsos TD
JACC Cardiovasc Imaging; 2015 May; 8(5):526-536. PubMed ID: 25890584
[TBL] [Abstract][Full Text] [Related]
9. Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines.
Neilan TG; Coelho-Filho OR; Pena-Herrera D; Shah RV; Jerosch-Herold M; Francis SA; Moslehi J; Kwong RY
Am J Cardiol; 2012 Dec; 110(11):1679-86. PubMed ID: 22917553
[TBL] [Abstract][Full Text] [Related]
10. Candidate Plasma Biomarkers to Detect Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors: A Case Control Study in the Dutch Childhood Cancer Survivor Study.
Leerink JM; Feijen EAM; Moerland PD; de Baat EC; Merkx R; van der Pal HJH; Tissing WJE; Louwerens M; van den Heuvel-Eibrink MM; Versluys AB; Asselbergs FW; Sammani A; Teske AJ; van Dalen EC; van der Heiden-van der Loo M; van Dulmen-den Broeder E; de Vries ACH; Kapusta L; Loonen J; Pinto YM; Kremer LCM; Mavinkurve-Groothuis AMC; Kok WEM
J Am Heart Assoc; 2022 Jul; 11(14):e025935. PubMed ID: 35861824
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular magnetic resonance characterisation of anthracycline cardiotoxicity in adults with normal left ventricular ejection fraction.
Harries I; Berlot B; Ffrench-Constant N; Williams M; Liang K; De Garate E; Baritussio A; Biglino G; Plana JC; Bucciarelli-Ducci C
Int J Cardiol; 2021 Nov; 343():180-186. PubMed ID: 34454967
[TBL] [Abstract][Full Text] [Related]
12. [Anthracycline-induced cardiotoxicity: cardiac MRI after treatment for childhood cancer].
Oberholzer K; Kunz RP; Dittrich M; Thelen M
Rofo; 2004 Sep; 176(9):1245-50. PubMed ID: 15346258
[TBL] [Abstract][Full Text] [Related]
13. Cardiac magnetic relaxometry versus ejection fraction in anthracycline-related cardiac changes: a systematic review and meta-analysis.
Yu C; Pathan S; Jeyaprakash P; Kritharides L; Pathan F; Negishi K
Open Heart; 2023 Jul; 10(2):. PubMed ID: 37507150
[TBL] [Abstract][Full Text] [Related]
14. Histogram Analysis of Native T
Wu CW; Wu R; Shi RY; An DA; Chen BH; Jiang M; Bacyinski A; Rahim A; Deen JM; Hu J; Han TT; Xu JR; Wu LM
J Magn Reson Imaging; 2019 Mar; 49(3):668-677. PubMed ID: 30142234
[TBL] [Abstract][Full Text] [Related]
15. Prospective multiparametric CMR characterization and MicroRNA profiling of anthracycline cardiotoxicity: A pilot translational study.
Harries I; Biglino G; Ford K; Nelson M; Rego G; Srivastava P; Williams M; Berlot B; De Garate E; Baritussio A; Liang K; Baquedano M; Chavda N; Lawton C; Shearn A; Otton S; Lowry L; Nightingale AK; Carlos Plana J; Marks D; Emmanueli C; Bucciarelli-Ducci C
Int J Cardiol Heart Vasc; 2022 Dec; 43():101134. PubMed ID: 36389268
[TBL] [Abstract][Full Text] [Related]
16. Anthracycline Therapy Is Associated With Cardiomyocyte Atrophy and Preclinical Manifestations of Heart Disease.
Ferreira de Souza T; Quinaglia A C Silva T; Osorio Costa F; Shah R; Neilan TG; Velloso L; Nadruz W; Brenelli F; Sposito AC; Matos-Souza JR; Cendes F; Coelho OR; Jerosch-Herold M; Coelho-Filho OR
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1045-1055. PubMed ID: 30092965
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults.
Dodos F; Halbsguth T; Erdmann E; Hoppe UC
Clin Res Cardiol; 2008 May; 97(5):318-26. PubMed ID: 18193371
[TBL] [Abstract][Full Text] [Related]
18. Long term cardiovascular magnetic resonance phenotyping of anthracycline cardiomyopathy.
Harries I; Biglino G; Baritussio A; De Garate E; Dastidar A; Plana JC; Bucciarelli-Ducci C
Int J Cardiol; 2019 Oct; 292():248-252. PubMed ID: 31006597
[TBL] [Abstract][Full Text] [Related]
19. Native Myocardial T1 as a Biomarker of Cardiac Structure in Non-Ischemic Cardiomyopathy.
Shah RV; Kato S; Roujol S; Murthy V; Bellm S; Kashem A; Basha T; Jang J; Eisman AS; Manning WJ; Nezafat R
Am J Cardiol; 2016 Jan; 117(2):282-8. PubMed ID: 26684511
[TBL] [Abstract][Full Text] [Related]
20. Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study.
aus dem Siepen F; Buss SJ; Andre F; Seitz S; Giannitsis E; Steen H; Katus HA; Kristen AV
Clin Res Cardiol; 2015 Aug; 104(8):640-7. PubMed ID: 25855392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
